deltatrials
Completed OBSERVATIONAL NCT05637632

Assessment of Recombinant HAT-RDT Specificity

Assesslebt of Recombinant HAT-RDT Specificity

Sponsor: Institute of Tropical Medicine, Belgium

Conditions Human African Trypanosomiasis
Updated 5 times since 2023 Last updated: Sep 27, 2023 Started: Sep 20, 2022 Primary completion: Feb 20, 2023 Completion: Feb 20, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05637632, this observational or N/A phase trial focuses on Human African Trypanosomiasis and remains completed. Sponsored by Institute of Tropical Medicine, Belgium, it has been updated 5 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2023 – ~Oct 2023 · 9 months · monthly snapshotRecruiting~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed

  2. Sep 2024 — Sep 2025 [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Oct 2023 — Jul 2024 [monthly]

    Completed

    Status: Recruiting → Completed

  5. Jan 2023 — Oct 2023 [monthly]

    Recruiting

    First recorded

Sep 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Institute of Tropical Medicine, Belgium
Data source: Institute of Tropical Medicine, Belgium

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations